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Abstract
In this study, we genetically characterized parathyroid adenomas with large glandular weights, for
which independent observations suggest pronounced clinical manifestations. Large parathyroid
adenomas (LPTAs) were deﬁned as the 5% largest sporadic parathyroid adenomas identiﬁed
among the 590 cases operated in our institution during 2005–2009. The LPTA group
showed a higher relative number of male cases and signiﬁcantly higher levels of total plasma
and ionized serum calcium (P!0.001). Further analysis of 21 LPTAs revealed low MIB1
proliferation index (0.1–1.5%), MEN1 mutations in ﬁve cases, and one HRPT2 (CDC73) mutation.
Total or partial loss of paraﬁbromin expression was observed in ten tumors, two of which also
showed loss of APC expression. Using array CGH, we demonstrated recurrent copy number
alterations most frequently involving loss in 1p (29%), gain in 5 (38%), and loss in 11q (33%).
Totally, 21 minimal overlapping regions were deﬁned for losses in 1p, 7q, 9p, 11, and 15q and
gains in 3q, 5, 7p, 8p, 16q, 17p, and 19q. In addition, 12 tumors showed gross alterations of entire
or almost entire chromosomes most frequently gain of 5 and loss of chromosome 11. While gain of
5 was the most frequent alteration observed in LPTAs, it was only detected in a small proportion
(4/58 cases, 7%) of parathyroid adenomas. A signiﬁcant positive correlation was observed
between parathyroid hormone level and total copy number gain (rZ0.48, PZ0.031). These
results support that LPTAs represent a group of patients with pronounced parathyroid
hyperfunction and associated with speciﬁc genomic features.
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Introduction
Primary hyperparathyroidism (PHPT) is one of the
most common endocrine disorders. Affected patients
typically present with high levels of ionized serum
calcium (S-Ca
2C) resulting from abnormally high
production of parathyroid hormone (PTH). In about
85% of cases, PHPT is due to an adenoma, multi-
glandular disease accounts for about 15% of cases, and
1% of patients have parathyroid carcinoma (DeLellis
et al. 2004). The disease is more common among
postmenopausal women, and screening studies in the
Swedish population have recognized PHPT in about
3.4% of this entity (Lundgren et al. 2002).
Previous studies have identiﬁed several causative
genetic events in PHPT contributing to the overall
understanding of the molecular pathogenesis of the
disease. Constitutional mutations are most common
not only in the tumor suppressor genes MEN1 (11q13;
Chandrasekharappa et al. 1997, Lemmens et al. 1997)
and HRPT2 (CDC73; 1q31.2; Carpten et al. 2002) but
also occur in CASR (3q21.1; Carling et al. 2000,
Simonds et al. 2002) and CDKN1B/p27 (12p13.1;
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commonly seen for MEN1 in parathyroid adenomas
(Heppner et al. 1997, Farnebo et al. 1998) and for
HRPT2 in parathyroid carcinomas (Howell et al. 2003,
Shattuck et al. 2003). Chromosome 11 rearrangements
between PTH a n dc y c l i nD 1 / PRAD1 have been
detected in a few cases of sporadic PHPT (Arnold
et al.1 9 8 9 ). In addition, two cases of somatic
translocations have been reported, including a
t(1;5)(p22;q32; O ¨ rndal et al. 1990)a n da
t(4;13)(q21;q14; Sammarelli et al. 2007).
Screenings of PHPT adenomas for genomic altera-
tions by comparative genomic hybridization (CGH;
Agarwal et al. 1998, Palanisamy et al.1 9 9 8 , Farnebo
et al. 1999, Hemmer et al. 2001, Garcia et al. 2002),
loss of heterozygosity (LOH; Cryns et al. 1995, Tahara
et al. 1996, 1997, Williamson et al. 1997, Carling et al.
1998, Dwight et al. 2000, 2002, Correa et al. 2002),
and array CGH (Yi et al. 2008) have identiﬁed
recurrent losses in 1p, 3q, 6q, 9p, 11p, 11q, and 15q
and gains of 16p and 19p.
While the risk groups of familial and malignant
PHPT have been partly elucidated at the molecular
level, less is known about sporadic parathyroid
adenomas with pronounced clinical and tumor pheno-
types. The terms Large or Giant adenoma have been
applied to describe cases of parathyroid tumors
with glandular weights far larger than the median
weight (650 mg) of unselected parathyroid adenomas
(Almquist et al. 2010). Publications describing cases of
large parathyroid tumors are so far limited; however,
male overrepresentation and increased biochemical
symptoms have been observed in limited case series
(Takeichi et al.1 9 8 3 , Lalanne-Mistrih et al. 2002,
Chiofalo et al. 2005, O’Neal et al. 2011). Several
studies have compared adenoma weight with bio-
chemical parameters. While some of these have
reported positive correlations between parathyroid
adenoma weight and levels of blood calcium (both
total plasma and S-Ca
2C) and PTH, other studies did
not reveal such correlations (Hedba ¨ck et al. 1995,
Bindlish et al. 2002, Randhawa et al. 2007).
Furthermore, increased parathyroid adenoma weight
was found to be associated with higher risk of death
(Hedba ¨ck et al. 1995). These circumstances imply that
large parathyroid adenoma (LPTA) patients could have
more aggressive clinical presentations. The aforemen-
tioned features of LPTA are also in line with
observations that parathyroid carcinomas generally
have a higher glandular weight than regular adenomas
(Kebebew 2001, Shane 2001, Robert et al. 2005,
Agarwal et al. 2006, Fernandez-Ranvier et al.
2007) and mostly have pronounced clinical symptoms.
In studies of sporadic parathyroid adenomas, associ-
ations have been made between molecular features and
tumor size. For example, one study reported differ-
ential microarray gene expression proﬁles in sporadic
parathyroid adenomas with different glandular weights
(Rosen et al. 2005).
The genetic background of LPTA has not been
characterized so far. In this study, we hypothesized that
large glandular weight and associated phenotypes may
be attributed to distinct genetic abnormalities. To test
our hypothesis, we characterized the mutation status of
the MEN1 and HRPT2 genes and applied high-
resolution array CGH to assess copy number altera-
tions (CNAs) in a panel of such tumors representing the
5% largest sporadic parathyroid adenomas in our
institution.
Materials and methods
LPTA cases
Cases withLPTA wereidentiﬁedfrompatientsoperated
for PHPT in the Karolinska University Hospital, Stock-
holm,Sweden,during2005–2009.Atotalof590patients
were identiﬁed who were without a known genetic
predisposition for the disease and had a parathyroid
adenomaofaspeciﬁedweightthathadbeenexaminedat
routine clinical histopathology (Table 1). From the
distribution of tumor sizes, we identiﬁed a group of 31
patients representing the 5% largest tumors with
glandular weight R4g( Supplementary Figure 1,s e e
section on supplementary data given at the end of this
article), which were classiﬁed as LPTAs.
Nineteen of these 31 LPTA cases were included in
genetic studies based on frozen tissue sample avail-
ability. Two additional LPTA tumors (cases 1 and 2)
were identiﬁed from our previous studies (Juhlin et al.
2006). Details for the 21 cases investigated here,
concerning demographic and biochemical parameters,
are presented in Table 2. One patient had a known
history of irradiation to the head and neck region
(case 8), two had renal stones (cases 4 and 20), and one
had renal failure (case 3). No clinical/family history
suggestive of multiple endocrine neoplasia or familial
PHPT syndrome could be elicited. Based on the
clinical, surgical, and pathological ﬁndings, all patients
were diagnosed with single gland disease classiﬁed as
parathyroid adenoma or atypical adenoma according to
the World Health Organization (WHO) criteria
(DeLellis et al. 2004). The diagnosis of atypical
adenoma was based on the histopathological features
such as capsular engagement, trabecular formation,
vascular invasion, ﬁbrous bands, and increased MIB1
L Sulaiman et al.: DNA copy numbers in large parathyroid adenomas
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www.endocrinology-journals.org 391proliferation index. None of the tumors presented a
diagnostic feature of parathyroid carcinoma, i.e. local
invasion, lymph node, or distant metastasis. For the
purpose of this study, routine histopathological reports
were reviewed, and routine slides were histopatholo-
gically reexamined for LPTA cases 1–21 (Table 2).
Tissue samples
All samples have been collected with oral informed
consent from the patients and documented in the
patients’ medical ﬁles. Ethical approval was granted
from the local ethics committee. Fresh frozen
parathyroid tissue samples stored at K80 8Cw e r e
obtained from the tissue biobank at the Karolinska
University Hospital. Representative sections from all
tumor samples studied were examined microscopically
by a histopathologist and shown to contain at least
70% tumor cells. Frozen tissue samples were obtained
from the 21 LPTA tumors and from three histopatho-
logically conﬁrmed nontumorous parathyroid tissues
(N1, N2, and N3) used as references for the gene
expression study. One of these (N1) was obtained
from the normal rim of a parathyroid adenoma, while
the other two (N2 and N3) were removed inadver-
tently during thyroid surgery. Parafﬁn-embedded
tumor tissue sections of LPTAs 3–21 were obtained
for immunohistochemistry, together with anonymous
sections of nontumor colon tissue and colon cancer
used as controls. In addition, 58 previously published
(Forsberg et al.2 0 0 5 , Haglund et al.2 0 1 0 )D N A
samples from parathyroid adenomas were used for
qPCR of chromosome 5 loci. Adenomas with a known
weight R4 g were not included.
DNA and RNA extraction
Total genomic DNA and total RNA were extracted
using DNeasy Blood and Tissue DNA isolation kit
(Qiagen AB) and mirVana miRNA Isolation Kit
(Ambion, Life Technologies, Applied Biosystems),
respectively, following the manufacturer’s protocols.
DNA and the RNA samples were quantiﬁed and
checked for quality using NanoDrop A100 (Thermo
Scientiﬁc, Waltham, MA, USA) and stored at K20 8C
until use.
Table 2 Clinical and histopathological details of the 21 LPTA cases
Calcium (mmol/l)
Case
no.
Age
(years)
Sex
(M/F)
Tumor
weight
(g) Total Ionized
P-PTH
(ng/l)
Original
diagnosis
Dominating
cell type
Histopathological
features of
atypical adenoma
1 75 F 6.54 2.85 – 711 Atypical
adenoma
Chief cell Trabecular
2 36 F 4.86 3.08 – 83 Adenoma Chief cell No
3 62 F 5.07 3.00 1.55 424 Adenoma Chief cell No
4 41 M 4.28 2.82 – 149 Adenoma Chief cell Trabecular
5 57 F 8.50 2.97 1.59 358 Adenoma Chief cell No
6 58 F 7.60 3.19 1.86 351 Adenoma Chief cell No
7 66 M 5.51 3.12 1.74 256 Adenoma Chief cell No
8 74 F 6.06 3.16 1.78 298 Adenoma Chief cell No
9 83 F 4.67 2.56 1.48 – Adenoma Oxyphilic No
10 65 F 7.50 2.92 1.41 147 Adenoma Chief cell Pleomorphism
11 72 M 12.30 3.00 1.63 1070 Adenoma Mixed Trabecular
12 59 M 11.60 3.12 1.85 1280 Atypical
adenoma
Chief cell Capsular
engagement
13 69 M 10.00 2.66 1.62 1400 Atypical
adenoma
Mixed Pleomorphism
14 54 F 13.50 3.19 1.85 245 Adenoma Chief cell Trabecular
15 38 F 7.00 2.81 1.58 248 Adenoma Mixed No
16 78 F 4.12 2.72 1.55 142 Adenoma Chief cell No
17 64 F 4.50 2.95 1.61 356 Adenoma Oxyphilic No
18 83 M 7.10 2.92 1.68 200 Adenoma Chief cell No
19 37 M 4.07 2.60 1.43 123 Adenoma Chief cell No
20 51 F 27.80 3.13 1.67 513 Adenoma Chief cell Trabecular
21 66 M 9.75 3.10 1.72 506 Adenoma Chief cell Fibrous bands
Agereferstoageatdiagnosis;M,male;F,female;–,notavailable;P-PTH,plasmaparathyroidhormone.Referencevalues:glandular
weight 0.04–0.06 g; total plasma calcium 2.15–2.55 mmol/l; ionized serum calcium 1.15–1.33 mmol/l; serum-PTH 10–65 ng/l.
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Protein expression of paraﬁbromin, APC, and Ki-67
wasdeterminedbyimmunohistochemistryonslidescut
at 4 mm thickness from parafﬁn-embedded blocks of
LPTAs 3–21 and controls using previously published
methodologies (Juhlin et al. 2006). The following
antibodies were used: APC rabbit monoclonal
(EP701Y, cat no. ab40778; Abcam, Cambridge, UK)
at a dilution of 1:100, paraﬁbromin mouse monoclonal
(2H1,catno.sc-33638;SantaCruzBiotechnology,CA,
USA) at a dilution of 1:20, and monoclonal MIB1
(Ki67, clone MIB1; Dako, Hamburg, Germany,
M7240) at a dilution of 1:200. Stained slides were
scanned with a virtual slide scanner (NanoZoomer 2.0-
HT, Hamamatsu, Japan) and viewed using NDP viewer
(NanoZoomer Digital Pathology). Exclusion of the
primary antibody as well as staining of normal colon
tissue were used as negative controls for all antibodies.
Colon cancer tissue was used as positive control of
Ki-67 expression, as well as parathyroid tissues with
known paraﬁbromin and APC expressions.
The result was evaluated by two or more
of the authors. MIB1 index was determined from
Ki-67-stained slides using both automated scoring of
scanned slides and counting of more than 2000 cells
from 5 or more randomly selected high power ﬁelds
(!40) in the same tumor. Paraﬁbromin staining was
scored as positive according to the previous reports,
total loss or partial loss of nuclear expression, and
in addition, nucleolar expression was evaluated
(Juhlin et al. 2006, 2010). APC was scored as positive
or negative as described in Juhlin et al. (2010).
Mutational analysis
The coding exons 2–10 of the MEN1 gene and all the
1–17 exons of the HRPT2 gene were sequenced in
both directions in LPTAs 1–21 using previously
published primer sequences and experimental con-
ditions with some modiﬁcations (Villablanca et al.
2004, Juhlin et al. 2006). PCR was performed in
25 ml reactions with 50 ng DNA, 1! PCR buffer,
200 mM of each dNTPs, 2 mM MgSO4, 0.2 mMo f
each primers, and 1 unit TaqDNA polymerase
(Invitrogen Life Technologies). PCR cycling con-
ditions included 94 8C for 30 s as initial denaturation
followed by 30 cycles (MEN1) or 35 cycles (HRPT2)
of 30 s of denaturation at 95 8C, annealing for 30 s at
52–58 8C, and extension for 30 s at 72 8C. All PCR
products were veriﬁed in 2% agarose gels, quantiﬁed,
and puriﬁed using ExoSAP-IT (USB-Affymetrix,
Cleveland, OH, USA). Sequencing was done using
BigDye terminators v. 1.1 sequencing kit (Applied
Biosystems, Foster City, CA, USA) in ABI 3730
PRISM DNA Analyzer (Applied Biosystems)
following the protocol of the manufacturer, and the
sequencing data were analyzed for mutations using
SeqScape version 2.5.0 (Applied Biosystems).
Array CGH and data analysis
Array CGH was performed for LPTA cases 1–21 using
human BAC 38K arrays generated at the SCIBLU
Genomics Centre at Lund University, Sweden (www.
lu.se/sciblu). These arrays contain 38 000 BAC clones
(CHORI BACPAC resources; http://bacpac.chori.org/
genomicRearray.php) arranged in a tiling fashion
resulting in a ﬁnal resolution of about 100–150 kb.
Laboratory procedures and data analyses were carried
out according to the previously established protocols
(www.lu.se/sciblu; Hashemi et al. 2011). Array CGH
slides were scanned in an Axon Scanner 4000A (Axon
Instruments, Burlingame, CA, USA) and the GenePix
Pro 6.0 software (Axon Instruments) was used for spot
identiﬁcation and image analysis. The resulting data
were imported into the BioArray Software Environ-
ment (BASE; http://base.thep.lu.se/) version 2 for
further analysis. CNAs were classiﬁed according to
log2 ratios applying the following thresholds: C0.25
for gain, K0.25 for loss, K1 for homozygous loss, and
C1 for ampliﬁcation. Recurrent aberrations were
deﬁned as aberrations identiﬁed in four or more of
the samples. Gross chromosomal changes were deﬁned
as changes that involved an entire or almost entire
chromosome. Minimal overlapping regions (MORs)
were deﬁned as the smallest recurrent CNAs according
to the deﬁnition by Rouveirol et al. (2006). Array CGH
data for all the 21 cases have been submitted in NCBI’s
Gene Expression Omnibus through GEO Series
accession number GSE36511 (http://www.ncbi.nlm.
nih.gov/geo/quary/acc.cgi).
Unsupervised hierarchical clustering was per-
formed using Pearson’s correlation distance matrix
(R software v2.12.2). Brieﬂy, this algorithm scans
through the entire array CGH dataset (sex chromosome
clones were excluded), calculates all pair-wise dis-
tances (degree of similarity regarding the copy number
changes), estimates the correlation efﬁciency for
each single clone spotted on the slide, and joins the
closest pair of samples. Then, it calculates the pair’s
distance to all other samples in the same pair-wise
approach to ﬁnd the two other closest pairs. This
process will be repeated until the distances for all the
samples are calculated and based on that, samples will
be reordered into a hierarchical structure represented
by a dendrogram tree (Quackenbush 2006).
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LPTAs 1–21 as well as 58 additional parathyroid
adenomas were analyzed by qPCR for copy number
detection at individual loci in regions of frequent
losses or gains in chromosomes 1, 5, and 11. Two
separate TaqMan Copy Number assays were used for
each of the loci RNF11 (Hs_cn 02893920 in intron
1/exon 2 and Hs_cn 02226491 in exon 3), TERT
(3078158 in exon 2 and 2818605 in exon 16), CARD6
(3056294 in exon 1 and 888745 in exon 3), PIK3R1
(2532703 in exon 6/intron 6 and 2558647 in exon 17),
APC (02966112 in intron 3/exon 4), LMNB1
(1652643 in exon 1 and 2496887 in exon 11), and
MEN1 (02189358 in exon 1 and 00270415 in exon 3).
Analyses were carried out according to the protocol
recommended by the manufacturer (Applied Biosys-
tems). Samples were ampliﬁed in a 7500 FAST
machine (Applied Biosystems), using a 96-well
format and the cycling conditions: 95 8C for 10 min,
and 40 cycles of (95 8C for 15 s and 60 8C for 1 min).
Each sample was ampliﬁed in triplicate in two
different experiments. Ampliﬁcation data were ana-
lyzed in the Sequence Detection Software SDS 2.2
(Applied Biosystems) followed by the CopyCaller
software V1.0 (Applied Biosystems) for prediction of
copy numbers. Data were normalized to RNaseP
(Hs_cn 4403326), which was ampliﬁed in parallel,
and calibrated to pooled normal DNA (Promega).
Negative controls constituted of ampliﬁcations with-
out sample DNA.
Quantitative reverse transcription PCR
(qRT-PCR)
Expression of the CARD6 gene was quantiﬁed in
LPTAs 1–21 and the three reference parathyroids N1–3
by qRT-PCR. In brief, 500 ng total RNA was reverse
transcribed to cDNA using High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems)
following the manufacturer’s instructions. qRT-PCR
was performed in triplicate applying standard amp-
liﬁcation conditions and a 96-well plate format in
a StepOnePlus real-time PCR machine (Applied
Biosystems). Normalization was done against the
housekeeping gene 36B4, which is known to be
ubiquitously expressed in parathyroid tissue (Forsberg
et al. 2005, Juhlin et al. 2006). Commercially available
assays were used for CARD6 (Hs00261581_m1;
Applied Biosystems) and 36B4 (Hs99999902_m1).
The expression of CARD6 was then quantiﬁed using
the Delta–Delta Ct method (2K DDCt).
Statistical analysis
All statistical calculations were performed using the
SPSS software (Statistical Software Package for
Windows, V.17; SPSS Inc., Chicago, IL, USA). The
nonparametric Mann–Whitney U test was used to
compare the demographic characteristics between
LPTAs and adenomas !4 g, while c
2 test was used
to investigate the differences in gender distribution.
Relationships between variables were assessed with
Spearman’s rank correlation test. P values below 0.05
were considered as statistically signiﬁcant.
Results
General characteristics for 590 PHPT cases operated
for a sporadic parathyroid adenoma during 2005–2009
at the Karolinska University Hospital, Stockholm,
Sweden, are summarized in Table 1. In the entire
material, the median adenoma weight, total plasma
calcium, and S-Ca
2C levels were signiﬁcantly higher
in male patients (0.60 vs 0.39 g; 2.81 vs 2.75, and 1.48
vs 1.44 mmol/l, respectively, P!0.001). However, no
statistically signiﬁcant difference in age at diagnosis
was observed. Thirty-one of the 590 cases (5%)
presented as LPTA weighing R4 g, while 559 cases
(95%) had an adenoma weight !4g( Supplementary
Figure 1). Comparison of demographic variables
revealed a higher relative number of male cases
among LPTAs (11 males/20 females, 35%) compared
with tumors !4 g (121 males/438 females, 22%;
PZ0.037). Furthermore, preoperative levels of
calcium (both total plasma and S-Ca
2C)w e r e
signiﬁcantly higher for LPTA cases than adenomas
!4 g (median 3.03 and 1.59 vs 2.80 and 1.47 mmol/l,
respectively, P!0.001; Table 1).
The 21 cases entered into the molecular character-
ization also tended to include relatively more male
cases (PZ0.075) and exhibited signiﬁcantly higher
S-Ca
2Clevels (median 1.64 vs 1.47 mmol/l, P!0.001;
Tables 1 and 2). Eighteen of these had been classiﬁed
as adenoma and three as atypical adenoma at the
original routine histopathological work-up. However,
review of all cases showed that some histopathological
features associated with atypical adenoma were also
present in six tumors classiﬁed as adenoma originally
(LPTAs 4, 10, 11, 14, 20, and 21, Table 2). These
included trabecular growth pattern, pleomorphism, and
ﬁbrous bands. However, the limited extent of these
features did not motivate a classiﬁcation as atypical
adenoma. In addition, automated and manual scoring
of Ki-67 immunoreactivity revealed low MIB1
proliferation index of 0.1–1.5 and 0.1–0.6%,
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was normalized in all cases and no recurrences were
detected at the follow-up.
Mutation screening of the MEN1 and HRPT2
genes
Detected mutations are illustrated in Supplementary
Figures 2 and 3, see section on supplementary data
given at the end of this article and detailed in
Table 3. Five MEN1 mutations were observed, which
were all predicted to lead to the introduction of
a premature stop codon and shorter protein. In the
HRPT2 gene, one missense mutation was revealed. In
addition, intronic base substitutions were detected in
HRPT2 (c1067-85COT intron 12 of case 1, c729C
50delAG in intron 7 of case 19, and c1418-17COG
in intron 15 of case 8).
Expression of paraﬁbromin and APC
Expression of the APC and paraﬁbromin proteins was
evaluated by immunohistochemistry in LPTAs 3–21
for which slides were available (Table 3). The ﬁndings
are illustrated in Fig. 1. Nine cases showed positive
paraﬁbromin expression, while ﬁve cases (7, 12, 13,
17, and 19) were negative and ﬁve cases (8, 10, 11, 14,
and 16) had partial loss of nuclear staining. For APC,
17/19 tumors were positive, while two tumors (cases
13 and 14) were negative for both nuclear and
cytoplasmic immunoreactivity.
Overall array CGH ﬁndings
All 21 LPTAs investigated in this study exhibited
CNAs including gains and losses. However, no
homozygous deletions (!K1) or high-level gains
(OC1) indicating ampliﬁcations were observed. First,
we investigated CNAs at the genomic loci of genes
Table 3 Results from immunohistochemistry, mutation screening, and array CGH in LPTAs 1–21
Mutation screening
a TotalchangebyarrayCGH(Mb)
Case
no.
IHC
paraﬁbromin
IHC
APC
CNA at
MEN1
CNA at
HRPT2 MEN1 HRPT2
Predicted
protein effect Losses Gains Total
1 – – No No Wt Wt – 187.6 100.2 287.8
2 – – No Loss c.1715del6
b Wt Stop codon at
nt 1825
798.5 308.6 1107.1
3 Pos Pos No No Wt Wt – 0.0 45.8 45.8
4 Pos Pos No No Wt c214COT p.Pro71Ser 10.4 1.0 11.4
5 Pos Pos Loss No c.1125del4 Wt Stop codon at
nt 1327
165.0 46.4 211.4
6 Pos Pos No No Wt Wt – 144.9 16.8 161.7
7 Total loss Pos No No Wt Wt – 1.9 0.3 2.2
8 Partial loss Pos No No Wt Wt – 3.8 14.1 17.9
9 Pos Pos No No Wt Wt – 127.7 78.7 206.4
10 Partial loss Pos Loss No Wt Wt – 171.4 2.8 174.2
11 Partial loss Pos Loss No Wt Wt – 267.8 445.9 713.7
12 Total loss Pos No No Wt Wt – 4.2 614.1 618.3
13 Total loss Neg No No Wt Wt – 49.8 785.4 835.2
14 Partial loss Neg No No Wt Wt – 19.9 3.6 23.4
15 Pos Pos No No Wt Wt – 38.0 6.3 44.3
16 Partial loss Pos No No Wt Wt – 207.9 508.4 716.3
17 Total loss Pos Loss Loss c.113del11 Wt Stop codon at
nt 334
526.1 389.8 915.9
18 Pos Pos No No c.398insT Wt Stop codon at
nt 537
123.7 3.0 126.7
19 Total loss Pos No No c.207del14 Wt Stop codon at
nt 333
1.8 1.5 3.2
20 Pos Pos Loss No Wt Wt – 176.2 2.3 178.5
21 Pos Pos No No Wt Wt – 210.9 175.6 386.5
Total 3237.4 3550.4 6787.8
IHC, immunohistochemistry; APC, adenomatous polyposis coli; Pos, positive; Neg, negative; Wt, wild type; CNA, copy number
aberration.
aNumbering was according to ensemble for the MEN1 (ENST00000312049) and HRPT2 (ENST00000367435) genes.
bThe mutation has been previously reported in Juhlin et al. (2006).
Endocrine-Related Cancer (2012) 19 389–407
www.endocrinology-journals.org 395k n o w nt ob ei m p l i c a t e di np a r a t h y r o i dt u m o r s
including MEN1, HRPT2, CASR, APC, CCND1, and
RB1. The MEN1 locus at 11q13 was deleted in 19% of
the cases, the HRPT2 locus at 1q31.2 in 9%, and the
CCND1 locus at 11q13.3 in 14%. The CASR locus at
3q21 showed normal array CGH proﬁles in all cases.
The APC locus at 5q22.2 was gained in 22.2% of the
cases and the RB1 locus in 13q14.2 was gained in 5%
and lost in 14% of LPTAs (Table 3).
We subsequently investigated CNAs in the entire
genome which revealed that all chromosomes were
involved and changes restricted to a small part of the
chromosome were more common than gross chromo-
somal aberrations involving an entire or almost entire
chromosome (Fig. 2). Recurrent losses were detected
on 1p, 7q, 11, 15q, and 21q, and gains were observed
on 3q, 5, 7p, 8p, 16q, 17p, and 19q with the longest
combined interval CNAs detected on chromosomes 1,
5, and 11 (Fig. 2). The total amplitude of CNAs
detected in a single tumor ranged from about 2.2 Mb
(case 7) to 1107.1 Mb (case 2) with a median of
178.5 Mb (Table 3).
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CD
EF
Figure 1 Photomicrographs showing examples of immunohistochemistry analysis of LPTAs. Positive (A) and negative (B)
cytoplasmic immunoreactivity in parathyroid adenomas for APC. Positive (C) and negative (D) staining of parathyroid adenomas for
nuclearparaﬁbromin. MIB1proliferationindex determined byKi-67immunostainingof aparathyroidadenoma(E) anda coloncancer
(F) used as positive control. All images are shown at !40 power.
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Figure 2 Overview of copy number alterations detected by
array CGH in 21 cases of LPTA. The whole-genome frequency
plot shows the proportion (in %) of gains (green) and losses
(red) detected in each individual chromosome from pter (left) to
qter (right). Individual chromosomes are shown in numbering
order from 1 (left) to 22 (right). Sex chromosomes (23 and 24)
were not included in the analyses.
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In order to identify chromosomal regions that may
harbor genes involved in the tumorigenesis of LPTAs,
we compared CNA patterns between tumors and
estimated MORs. MORs that largely or completely
overlapped with known normal copy number poly-
morphisms according to the Database of Genomic
Variants (http://projects.tcag.ca/variation/)w e r e
excluded. In addition, we identiﬁed 11 MORs of loss
and ten MORs of gain that were supported by recurrent
CNAs in four or more LPTAs (Table 4).
Copy number losses involving the short arm of
chromosome 1 was a frequent ﬁnding and detected in
six cases (29%; Fig. 3). However, loss of 1q was
infrequent and chromosome 1 rarely showed any gains.
Three MORs of loss were identiﬁed on the short arm of
chromosome 1. A 3.2 Mb region in 1p35.1–2, a 4.7 Mb
interval in 1p32.3, and a 22.6 Mb region in 1p36.31–
35.3 were each involved in 6/6 cases with loss in 1p
(Fig. 3). The 1p32.3 region harbors several genes, such
as the tumor suppressor genes CDKN2C (P18) and
RNF11.
Chromosome 5 displayed gains in eight LPTAs
(38%), which in six cases encompassed almost the
entire chromosome (Fig. 4). Three MORs of gains
were detected in chromosome 5. One MOR was
deﬁned at 5p13.1 (0.6 Mb) and the other two MORs
at 5q23.2 (0.2 Mb) and 5q12.1–13.1 (2.5 Mb). The
MOR located at 5q23.2 was gained in 7/8 cases with
gain of chromosome 5 and overlapped few genes most
importantly LMNB1, while the other MOR of gain
identiﬁed at 5q12.1–13.1 was observed in six LPTAs
(29%) and overlapped several genes among others,
PIK3R1.
Chromosome 11 displayed copy number losses in
seven of the LPTAs (33%) involving the q-arm in all
the seven cases and the p-arm in ﬁve cases (Fig. 5).
Gains of chromosome 11 were detected infrequently.
Four MORs of losses were identiﬁed. The MOR in
11p15.5–p11.2 including almost the entire p-arm was
deleted in 5/7 cases with the loss of chromosome 11.
The three MORs of losses in 11q were deﬁned at
11q13.1–2 (4.9 Mb), 11q14.1–2 (1.0 Mb), and
11q22.1–24.3 (30.4 Mb; Table 4). The 11q14.1–2
interval including PICALM was involved in 7/7 cases
with 11q loss, while the 11q13.1–2 region that
encompasses the MEN1 gene was deleted in four cases.
Large-scale chromosomal alterations
CNAs corresponding to large-scale chromosomal
changes were noted in a subset of the 21 LPTAs
screened with array CGH and revealed as losses or
Table 4 Most common recurrent MORs detected by array CGH in 21 LPTA cases
Cytoband Start clone End clone
Position
(Mb)
Size
(Mb)
No. of
clones
Frequency
%
Selected
for qPCR
Losses
1p36.31–p35.3 CTD-2280K14 RP13-485J14 6.1–28.7 22.60 281 29
1p35.2–p35.1 RP11-51C12 RP11-125D21 30.8–34.1 3.16 36 29
1p32.3 RP11-183G22 RP11-12C19 50.4–55.2 4.71 53 29 RNF11
7q11.22–q11.23 RP11-746H3 RP11-379D10 71.1–75.3 4.31 73 19
9p21.3–p13.3 RP11-560J9 RP11-475O13 32.9–34.4 1.43 15 19
11p15.5–p11.2 RP11-371C18 RP11-56E13 1.3–48.1 46.80 666 24
11q13.1–q13.2 RP11-472L10 RP11-259D17 63.3–68.2 4.88 55 19 MEN1
11q14.1–q14.2 RP11-726H9 RP11-317J19 85.1–86.1 1.00 10 33
11q22.1–q24.3 RP11-463H5 CTD-2120F5 99.8–130.2 30.40 363 29
15q11.1–q11.2 RP11-207G6 RP11-59F20 18.2–20.3 2.01 39 28
15q15.1–q21.1 RP11-451G20 RP11-226C3 38.5–42.9 4.32 58 19
Gains
3q22.3–q26.33 RP11-809A16 RP11-139K3 140.1–183.8 43.70 542 19
3q27.1 RP11-778D9 RP11-328G15 185.1–186.0 0.63 11 24
5p13.1 RP11-94C22 RP11-19F12 40.8–41.4 0.62 6 29 CARD6
5q12.3–q13.1 RP11-475K24 RP11-417A16 65.9–68.3 2.50 48 29 PIK3R1
5q23.2 RP11-772E11 RP11-368F9 125.9–126.1 0.20 4 33 LMNB1
7p14.1 RP11-556H1 RP11-170L15 37.6–38.1 0.51 4 19
8p23.1 RP11-231L4 RP11-672P7 6.8–7.7 0.87 9 23
16q24.2–24.3 RP11-483N11 RP11-180K1 86.7–87.9 0.13 9 19
17p13.1 RP11-558E15 RP13-696M16 6.9–8.0 1.02 16 23
19q13.2–q13.31 RP11-108I20 RP11-427D11 47.1–48.3 1.14 17 19 DEDD2
Mb, mega base pairs; MOR, minimal overlapping region.
Endocrine-Related Cancer (2012) 19 389–407
www.endocrinology-journals.org 397gains that involved an entire or almost entire
chromosome. A total of 53 such large-scale changes
were detected in 12 cases, ranging from 1 to 10
aberrations per tumor. By contrast, in the remaining
nine tumors, no large-scale changes were detected.
The most common large-scale aberrations were
gain of chromosome 5 (29%), 3 (19%), 7 (14%),
and 8 (14%) and loss of chromosome 11 (24%),
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Chromosomes 2, 14, and 16 did not display any
large-scale aberrations. Seven tumors showed one or
more such gains which in 6/7 cases included
chromosome 5. Ten tumors showed losses which
in ﬁve cases involved chromosomes 11, but only
one of these tumors overlapped with gain of
chromosome 5 (case 11).
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parameters
Unsupervised hierarchical clustering for all array CGH
data resulted in two main clusters (Fig. 6B). Cluster 1
included six cases that were exclusively females. Four
of the six cases in Cluster 1 showed gross chromo-
some 11 loss without gross chromosome 5 gain.
Cluster 2 included 15 cases of which eight were male.
While only one case (case 11) from Cluster 2 had gross
chromosome 11 loss, all the six cases with entire
chromosome 5 gain fell into this cluster.
The detected CNAs were compared with clinical
characteristics for the 21 LPTA cases concerning
amplitude of changes, cluster groups, subchromosomal
changes, and large-scale aberrations. A statistically
signiﬁcant positive correlation between PTH levels and
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(rZ0.48, PZ0.031; Supplementary Figure 4,s e e
section on supplementary data given at the end of
this article). No statistically signiﬁcant differences in
biochemical or histopathological characteristics were
observed between the cases in Clusters 1 and 2.
Validation by qPCR
qPCR-based copy number assays were used to validate
selected regions identiﬁed as recurrently lost or gained
by array CGH in the set of 21 LPTAs (Table 5). For the
4.7 Mb MOR of loss in 1p32.3, we selected the RNF11
gene for validation. Loss of RNF11 showed a high
concordance with array CGH ﬁndings and could be
conﬁrmed in 4/6 (67%) cases with 1p32.3 loss. To
validate the loss of 11q, we selected only a well-known
gene, MEN1, located in the 4.8 Mb MOR of loss in
11q13.1–2. Correlation between CNAs detected by
array CGH and qPCR was revealed in 4/4 (100%) cases
with loss at this speciﬁc locus. For chromosome 5, we
selected ﬁve gene loci including TERT and CARD6 on
the p-arm and PIK3R1, APC, and LMNB1 on the q-arm
(Table 5). The gains observed by array CGH were also
demonstrated by qPCR in 4/6 (67%) cases for TERT,3 /
6 (50%) for CARD6, 5/6 (83%) for PIK3R1, 5/6 (83%)
for APC, and 4/7 (57%) for LMNB1.
We also selected chromosome 5 for further analysis
in an extended series of parathyroid adenoma cases.
This was based on the ﬁnding of chromosome 5 gain as
the most common aberration detected in this group of
LPTA tumors and which has not been previously
reported as a frequent alteration in parathyroid
adenomas (Palanisamy et al. 1998, Garcia et al.
2002). Out of 58 cases, only four cases showed copy
number gains for at least one chromosome 5 assay
(Table 5).
CARD6 gene expression
Given the frequent gain of chromosome 5, expression
of the CARD6 gene was quantiﬁed in LPTAs 1–21
using qRT-PCR. Five LPTAs (cases 3, 4, 18, 20, and
21) displayed more than twofold increased expression
compared with the reference parathyroid tissues
(Fig. 7).
Discussion
The clinical entity of LPTA has not been well deﬁned,
and in previous studies, different cutoff points for
glandular sizes have been applied to deﬁne abnormally
LPTAs (Lalanne-Mistrih et al. 2002, Rosen et al.
2005). The smallest cutoff used in a recently published
paper was 2 g (O’Neal et al. 2011). In our study, we
deﬁned 4 g as the cutoff based on the distribution of
glandular weights for parathyroid adenomas operated
in our institution during the period 2005–2009. This
group of cases, representing the 5% largest PHPT
adenomas, exhibited signiﬁcantly increased calcium
levels and a relatively higher male to female ratio.
These observations are well in agreement with the
previous studies on large-sized PHPT adenomas
(Takeichi et al. 1983, Lalanne-Mistrih et al. 2002,
Chiofalo et al. 2005, O’Neal et al. 2011).
As part of the genetic characterization of LPTAs, we
screened the MEN1 and HRPT2 genes for mutations
as these are known to be frequently mutated in
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1998). This revealed ﬁve cases with an MEN1 mutation
predicted to give a truncated menin protein and one
case with a missense HRPT2 mutation in agreement
with the previous reports of frequent MEN1 mutations
and rare HRPT2 mutations in parathyroid adenomas
(Carpten et al. 2002, Howell et al. 2003, Krebs et al.
2005, Bradley et al. 2006, Juhlin et al. 2006). None of
the patients for which a MEN1 or HRPT2 mutation was
detected presented clinical indications or a family
history indicating a familial form of the disease, which
would suggest that the mutations are somatic.
However, as constitutional DNA was not sequenced,
the presence of constitutive mutations cannot be
determined. Hence, the potential risk of heritable
disease should be considered, especially in the HRPT2
mutated case for which unexpected mutation carriers
are known to occur. Two MEN1 mutated cases (cases
5 and 17) exhibited CNA at the MEN1 locus by qPCR
(Table 3) and/or array CGH (Fig. 5) together with
presence of sequencing traces for the wild-type allele
(Supplementary Figure 2). The wild-type sequencing
trace could result from one or more factors such as
contaminating normal tissue, variable ampliﬁcation
efﬁciency of the different alleles, subclonal copy
number loss in the tumor cells, or the tumors are
hyperdiploid so that a copy number loss still leaves
more than one allele in some or all tumor cells.
Using array CGH, we demonstrate recurrent CNAs
corresponding to gross chromosomal and/or subchro-
mosomal alterations in sporadic LPTAs. This approach
is widely used to identify net CNAs targeting cancer-
related genes but does not identify copy number neutral
alterations that could be approached by screening for
LOH using, e.g. SNP arrays. In our study, CNAs were
detected in all cases with frequent involvement of
chromosomes 1, 5, and 11. Among these, gain of
chromosome 5 was the most common and unique
alteration detected in 38% of the 21 LPTAs analyzed.
The array CGH proﬁles detected conﬁrmed several
ﬁndings from the previous reports of chromosomal
imbalances by LOH or metaphase CGH and in addition
identiﬁed chromosome 5 gain as a recurrent aberration
in the LPTA entity. Aberrations restricted to small
chromosomal regions were also frequently observed,
which may be attributed to the increased resolution
of array CGH compared with LOH and metaphase
CGH. While the only published array CGH analysis
of parathyroid tumors has focused on chromosome 11
(Yi et al.2 0 0 8 ), comparison to published array CGH
dataforotherchromosomescannotbereadilyperformed.
Interestingly, gain of chromosome 5 was observed
as the most frequent (38%) aberration and commonly
involved the entire or large parts of the chromosome.
By contrast, this aberration has not been reported in
high frequency in previous studies of regular para-
thyroid adenomas. For example, studies based on
Table 5 Details and results for qPCR analyses
Location Alteration detected
Gene locus Mb Cytoband Type LPTA cases 1–21 Adenomas (nZ58)
Chromosome 1
RNF11 51.7 1p32.3 Loss 7/21 cases (33%) ND
Chromosome 5
TERT 1.2 5p15.33 Gain 5/21 cases (24%) ND
CARD6 40.8 5p13.1 Gain 4/21 cases (19%) 0/58 cases (0%)
PIK3R1 67.5 5q13.1 Gain 11/21 cases (52%) 2/58 cases (3%)
APC 112.0 5q22.2 Gain 6/21 cases (29%) 2/58 cases (3%)
LMNB1 126.1 5q23.2 Gain 4/21 cases (19%) 0/58 cases (0%)
Chromosome 11
MEN1 64.6 11q13.1 Loss 6/21 cases (29%) ND
Reference gene
RNaseP 19.9 14q11.2
Reported alterations were observed by one or both assays used for each gene. ND, not determined.
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chromosome 5 in !14% of parathyroid adenomas
(Palanisamy et al. 1998, Garcia et al. 2002). However,
in parathyroid carcinomas, this abnormality was
revealed in varying frequencies from !10% (Agarwal
et al. 1998, Kyto ¨la ¨ et al.2 0 0 0 ). The frequent
occurrence of chromosome 5 gain in LPTAs compared
with PHPT adenomas is unlikely to result from
different resolutions of the applied techniques but
may rather be regarded as a nonrandom chromosomal
change characteristic of LPTAs or subsets among
LPTAs. Copy number gains of chromosome 5 have
also been associated with several other tumors such as
low-grade renal cell carcinoma (Reutzel et al. 2001),
adrenocortical tumors (Kjellman et al.1996), as well as
bronchial and gastrointestinal carcinoids (Voortman
et al. 2010). Although the target gene(s) for chromo-
some 5 gain are presently unknown, several genes with
known or potential involvement in human cancer are
located on this chromosome. For example, the MOR at
5q23.2 that was gained in 33% of cases included the
LMNB1 gene encoding the lamin B1 protein expressed
in tumors and plasma from hepatocellular carcinoma
patients (Sun et al. 2010). Furthermore, the MOR at
5p13.1 includes the CARD6 gene, which has been
found overexpressed on the protein level in other
cancers such as esophageal, gastric, and colorectal
cancers (Kim et al. 2010). CARD6 plays an important
role in the activation of NF-kB signaling, involved in
proliferation, differentiation, and apoptosis (Aggarwal
2004) and deregulated in many tumor types including
parathyroid tumors (Corbetta et al. 2005). The present
observations of CARD6 overexpression as well as copy
number gains suggest that evaluation of the protein
expression could be valuable to further study the
possible involvement of this gene in parathyroid
tumors.
Copy number loss in the short arm of chromosome 1
was recurrently observed in the LPTAs studied (29%)
in agreement with most previous CGH and LOH
studies of parathyroid adenomas (Cryns et al. 1995,
Agarwal et al. 1998, Farnebo et al. 1999). Similar to
observations in regular adenomas, losses in 1p mainly
affected the distal part, in contrast to parathyroid
carcinomas where deletions cluster in the central part
of 1p (Kyto ¨la ¨ et al. 2000, Va ¨lima ¨ki et al. 2002). Loss in
the short arm of chromosome 1 has been reported for
many different cancer types, among others by LOH in
the neuroendocrine tumors such as phaeochromocy-
toma and medullary thyroid carcinoma (Mathew et al.
1987, Khosla et al. 1991) as well as neuroblastoma
(Fong et al. 1989). The genes LCK, EPS15, RNF11,
and CDKN2C (P18) are potential candidates located
in 1p, of which CDKN2C (P18) has been screened for
point mutations with negative results (Tahara et al.
1997). The failure to detect frequently mutated target
genes in 1p in parathyroid adenoma and other cancers
may suggest the involvement of multiple target genes
and/or possibly other inactivating mechanisms such
as chromosomal rearrangements or inactivation by
epigenetic mechanisms.
The LPTAs demonstrated frequent loss in chromo-
some 11, with preferential involvement of the long
arm, comparable to the previously published ﬁndings
in parathyroid adenomas based on the metaphase
CGH, array CGH, and LOH analyses (Friedman
et al. 1992, Cryns et al. 1995, Agarwal et al. 1998,
Palanisamy et al. 1998, Farnebo et al. 1999, Dwight
et al. 2000, Correa et al. 2002, Yi et al. 2008).
Interestingly, LOH studies on parathyroid adenomas
have demonstrated larger parathyroid adenoma
weights in cases with 11q LOH (Friedman et al.
1992, Va ¨lima ¨ki et al. 2002). The MEN1 gene is known
to be mutated in the majority of parathyroid adenomas
with loss within the 11q13 region. In the LPTAs,
the MEN1 locus was lost in the majority of cases with
11q loss; however, loss was more frequently observed
within distal chromosome 11 at 11q14 and 11q22.1–
q24.3 (Fig. 5). Similar observations suggesting an
additional locus on chromosome 11 outside the MEN1
gene were reported using array CGH in parathyroid
adenomas (Yi et al. 2008).
Based on the similarity in glandular size between
LPTAs and parathyroid carcinomas, it has been
speculated whether large parathyroid tumors could
also be associated with a malignant potential (Hundahl
et al. 1999). None of the LPTAs studied exhibited
histopathological features of parathyroid cancer and,
although the follow-up time is limited, no recurrences
have been detected at the follow-up. To further
approach this question, we determined MIB1 prolifer-
ation index as well as expression of the paraﬁbromin
and APC proteins, each of which have been associated
with parathyroid malignancy. The proliferation index
was found to be low, below 1.5%, in all LPTAs
studied. This observation would suggest a benign
behavior of the LPTAs based on the previous reports
of low MIB1 index in parathyroid adenomas compared
with carcinomas (Lloyd et al. 1995). Total or partial
loss of paraﬁbromin reactivity was observed in ten
tumors, two of which also showed loss of APC
immunoreactivity. However, this was not accompanied
by HRPT2 mutations, supporting the previous reports
that loss of paraﬁbromin immunoreactivity does not
necessarily reﬂect an HRPT2 mutation (Gill et al.
2006, Zhang et al. 2006, Juhlin et al. 2007, 2010).
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atypical adenoma, two were available for IHC analyses
(cases 12 and 13). Both these cases exhibited total
loss of paraﬁbromin expression, and in case 13, this
feature was accompanied by loss of APC expression.
These ﬁndings are fully in line with the previous
reports regarding atypical adenomas and paraﬁbromin
and APC immunoreactivity (Juhlin et al. 2010). As loss
of APC and paraﬁbromin expression are associated
with parathyroid carcinoma and atypical adenoma
(Juhlin et al. 2007, 2010), our observations suggest
that a subset of LPTAs share molecular characteristics
with these entities.
Comparison of the genomic proﬁles, MEN1 and
HRPT2 mutations, and APC and paraﬁbromin
expression of LPTAs in this study with published
studies of regular parathyroid adenomas and parathy-
roid carcinomas suggest the presence of overlapping
as well as distinguishing features. Hence, LPTAs
were similar to adenomas concerning frequent MEN1
mutations, infrequent HRTP2 mutations, and losses of
distal 1p and 11, and more like carcinomas concerning
loss of APC and paraﬁbromin expression and loss
of chromosome 13. However, gain of chromosome 5
was common between LPTA and carcinoma. Taken
together, these observations suggest that LPTAs
exhibit partly overlapping and partly distinguishing
genomic features compared with adenomas and
carcinomas.
The 21 LPTAs fell into two main clusters based
on the array CGH data, which in large corresponded
to the presence/absence of large-scale chromosomal
aberrations. This observation may suggest that gain
of chromosome 5 reﬂect a genetic pathway for a
subset of LPTAs that is independent of chromosome
11 loss. It can also be noted that all male cases fell
into Cluster 2 characterized by chromosome 5 gain.
Interestingly, a positive correlation was also observed
between PTH level and total amplitude of copy
number gain. However, gender-related differences
and statistical associations to PTH levels for array
CGH abnormalities were based on a limited sample set
and should therefore be substantiated or rejected in
a larger panel of LPTAs.
In summary, we conclude that LPTAs could
constitute a subset of parathyroid lesions associated
with pronounced PHPT features and speciﬁc genomic
aberrations.
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